Balzarini Jan, Das Kalyan, Bernatchez Jean A, Martinez Sergio E, Ngure Marianne, Keane Sarah, Ford Alan, Maguire Nuala, Mullins Niki, John Jubi, Kim Youngju, Dehaen Wim, Vande Voorde Johan, Liekens Sandra, Naesens Lieve, Götte Matthias, Maguire Anita R, Arnold Eddy
Rega Institute for Medical Research and
Center for Advanced Biotechnology and Medicine and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ 08854-8020;
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3475-80. doi: 10.1073/pnas.1420233112. Epub 2015 Mar 2.
Polymerases have a structurally highly conserved negatively charged amino acid motif that is strictly required for Mg(2+) cation-dependent catalytic incorporation of (d)NTP nucleotides into nucleic acids. Based on these characteristics, a nucleoside monophosphonate scaffold, α-carboxy nucleoside phosphonate (α-CNP), was designed that is recognized by a variety of polymerases. Kinetic, biochemical, and crystallographic studies with HIV-1 reverse transcriptase revealed that α-CNPs mimic the dNTP binding through a carboxylate oxygen, two phosphonate oxygens, and base-pairing with the template. In particular, the carboxyl oxygen of the α-CNP acts as the potential equivalent of the α-phosphate oxygen of dNTPs and two oxygens of the phosphonate group of the α-CNP chelate Mg(2+), mimicking the chelation by the β- and γ-phosphate oxygens of dNTPs. α-CNPs (i) do not require metabolic activation (phosphorylation), (ii) bind directly to the substrate-binding site, (iii) chelate one of the two active site Mg(2+) ions, and (iv) reversibly inhibit the polymerase catalytic activity without being incorporated into nucleic acids. In addition, α-CNPs were also found to selectively interact with regulatory (i.e., allosteric) Mg(2+)-dNTP-binding sites of nucleos(t)ide-metabolizing enzymes susceptible to metabolic regulation. α-CNPs represent an entirely novel and broad technological platform for the development of specific substrate active- or regulatory-site inhibitors with therapeutic potential.
聚合酶具有结构上高度保守的带负电荷氨基酸基序,这对于Mg(2+)阳离子依赖的(d)NTP核苷酸催化掺入核酸是严格必需的。基于这些特性,设计了一种核苷单膦酸支架,即α-羧基核苷膦酸(α-CNP),它能被多种聚合酶识别。对HIV-1逆转录酶的动力学、生化和晶体学研究表明,α-CNPs通过一个羧酸根氧、两个膦酸根氧以及与模板的碱基配对来模拟dNTP的结合。特别是,α-CNP的羧基氧充当dNTPs的α-磷酸氧的潜在等效物,α-CNP膦酸基团的两个氧螯合Mg(2+),模拟dNTPs的β-和γ-磷酸氧的螯合。α-CNPs (i)不需要代谢激活(磷酸化),(ii)直接结合到底物结合位点,(iii)螯合两个活性位点Mg(2+)离子中的一个,并且(iv)可逆地抑制聚合酶催化活性而不掺入核酸。此外,还发现α-CNPs与易受代谢调节的核苷(酸)代谢酶的调节(即变构)Mg(2+)-dNTP结合位点选择性相互作用。α-CNPs代表了一个全新的、广泛的技术平台,用于开发具有治疗潜力的特异性底物活性或调节位点抑制剂。